Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253295 | 0.84 | TAAR1 (0.50) | TAAR1HTR2AHTR2CHTR2BHRH1 | |
| SCHEMBL16953547 | 0.82 | HCRTR1 (0.40) | HCRTR1HCRTR2DRD2SLC6A3SLC6A2 | |
| SCHEMBL1254108 | 0.81 | TAAR1 (0.61) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL1254447 | 0.79 | MCL1 (0.41) | HCRTR1HCRTR2HTR2ASLC6A3SLC6A2 | |
| SCHEMBL1299443 | 0.77 | TAAR1 (0.58) | TAAR1HCRTR1HCRTR2HTR2AHRH1 | |
| SCHEMBL16479216 | 0.76 | SCN8A (0.42) | HCRTR1HCRTR2HTR2AHTR2B | |
| SCHEMBL6463455 | 0.76 | TAAR1 (0.43) | TAAR1HTR2AHTR2CHTR2BHRH1 | |
| SCHEMBL16960643 | 0.75 | L3MBTL1 (0.36) | HCRTR1HCRTR2DRD2SLC6A3SLC6A2 | |
| SCHEMBL1252234 | 0.75 | TAAR1 (0.56) | TAAR1HTR2AHTR2CHTR2BHRH1 | |
| SCHEMBL1251942 | 0.74 | TAAR1 (0.55) | TAAR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848614-A2 | Acrylamide derivatives as antibiotic agents | Debiopharm International SA (CH) | 2015-03-18 | — | — | EP | disclosed |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8450307-B2 | Therapeutic agents, and methods of making and using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-05-28 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-1828167-A2 | ACRYLAMIDE DERIVATIVES AS ANTIBIOTIC AGENTS | Affinium Pharmaceuticals, Inc. (CA) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007053131-A2 | ACRYLAMIDE DERIVATIVES AS ANTIBIOTIC AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-05-10 | — | — | WO | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | MCL1, DHFR, ANXA5 | TAAR1 4842/4885HCRTR1 4337/4885HCRTR2 4557/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | TAAR1 4779/4885HCRTR1 4634/4885HCRTR2 4812/4885 |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | MCL1, DHFR, ANXA5 | TAAR1 4842/4885HCRTR1 4337/4885HCRTR2 4557/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | TAAR1 4779/4885HCRTR1 4634/4885HCRTR2 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.